IMMP

#3773
Immutep Limited - American Depositary Shares
0.4 4 USD
-2.22%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
0.44
0.44
Yıllık Aralık
0.29
3.53
Günlük Değişim
-2.22%
Aylık Değişim
-8.33%
6 Aylık Değişim
-77.44%
Yıllık Değişim
-77.32%
Önceki Kapanış
0.4 5
Open
0.4 4
Düşük
0.4 4
High
0.4 4
Hacim
9
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler
Çeyreklik Yıllık
Gelir tablosu Bilanço Nakit akışı
Değer 20202021202220232024 TTM

Immutep Limited - American Depositary Shares

Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis.

Haberler